Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia
SMS
Effect of Daily SMS Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia
1 other identifier
observational
339
1 country
25
Brief Summary
This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2009
Shorter than P25 for all trials
25 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 31, 2009
CompletedFirst Posted
Study publicly available on registry
April 1, 2009
CompletedStudy Start
First participant enrolled
April 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2010
CompletedMarch 24, 2010
March 1, 2010
11 months
March 31, 2009
March 23, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Morisky Green Questionnaire
baseline, at months 3 and 6
Secondary Outcomes (2)
Clinical Global Impression- Schizophrenia (CGI-SCH)
baseline, at months 3 and 6
Register of Adherence to Treatment (RAT)
baseline, at months 3 and 6
Eligibility Criteria
Stabilized outpatients with a diagnosis of schizophrenia
You may qualify if:
- Male or female patients older than 18 years
- With a diagnosis of schizophrenia (DSM-IV TR criteria)
- Stabilized out-patients
- Under oral antipsychotic monotherapy
You may not qualify if:
- Administration of a depot antipsychotic drug
- Suicide risk
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (25)
Research Site
Alicante, Alicante, Spain
Research Site
Almería, Almeria, Spain
Research Site
Barcelona, Barcelona, Spain
Research Site
Berga, Barcelona, Spain
Research Site
Sabadell, Barcelona, Spain
Research Site
Burgos, Burgos, Spain
Research Site
Santander, Cantabria, Spain
Research Site
Córdoba, Cordoba, Spain
Research Site
Granada, Granada, Spain
Research Site
León, Leon, Spain
Research Site
Lleida, Lerida, Spain
Research Site
Madrid, Madrid, Spain
Research Site
Málaga, Malaga, Spain
Research Site
Murcia, Murcia, Spain
Research Site
Pamplona, Navarre, Spain
Research Site
Oviedo, Oviedo, Spain
Research Site
Palma Mallorca, Palma Mallorca, Spain
Research Site
Salamanca, Salamanca, Spain
Research Site
Seville, Sevilla, Spain
Research Site
Tarragona, Tarragona, Spain
Research Site
Toledo, Toledo, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Valladolid, Valladolid, Spain
Research Site
Zamora, Zamora, Spain
Research Site
Calatayud, Zaragoza, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
March 31, 2009
First Posted
April 1, 2009
Study Start
April 1, 2009
Primary Completion
March 1, 2010
Study Completion
March 1, 2010
Last Updated
March 24, 2010
Record last verified: 2010-03